Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on May 10, 2022
May 03, 2022 16:05 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and...
Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Society of Toxicology 61st Annual Meeting
March 28, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, March 28, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today presented two posters highlighting nonclinical data...
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
February 28, 2022 16:05 ET
|
Atea Pharmaceuticals, Inc.
Developing bemnifosbuvir (AT-527), a nucleotide analog, as preferred backbone of combination therapy for COVID-19, progressing to Phase 2 combination clinical trial in 2H 2022 Initiating Phase 2...
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 28, 2022
February 22, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and...
Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development
February 10, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for...
Atea Pharmaceuticals to Present at 11th Annual SVB Leerink Global Healthcare Conference
February 09, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct...
Atea Pharmaceuticals Announces Publication of Data Supporting Bemnifosbuvir’s (AT-527) Novel Mechanism of Action Against SARS-CoV-2 in Nature Communications
February 02, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that new data highlighting bemnifosbuvir...
Atea Pharmaceuticals Highlights Strategic Priorities for 2022
January 07, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
COVID-19: Planning global Phase 2 outpatient trial for bemnifosbuvir (AT-527) designed to support anticipated combination trials HCV: Obtained from Merck an exclusive worldwide license to ruzasvir...
Atea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
Atea Pharmaceuticals Added to the Nasdaq Biotechnology Index
December 17, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the company has been added to the...